Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518907 · ClinicalTrials.gov registry record · Phase 1
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT01518907 is a Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 99 participants, below the 152-participant average among 5 other Cellulite trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01518907, a Phase 1 study of Cellulite and Edematous Fibrosclerotic Panniculopathy, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, effectiveness, pharmacokinetics, and immunogenicity of AA4500 at increasing doses and concentrations in the treatment of adult women with cellulite.
Conditions Studied
Interventions
- BIOLOGICAL COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center, Inc - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518907
The ClinicalTrials.gov registry entry for NCT01518907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 5 other Cellulite trials with a reported enrollment target (35% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cellulite appearing as the primary indexed condition, and to 1 intervention - of which COLLAGENASE CLOSTRIDIUM HISTOLYTICUM is the first listed.
NCT01518907 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01518907 about?
NCT01518907 is a clinical study titled "The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)". This study will evaluate the safety, effectiveness, pharmacokinetics, and immunogenicity of AA4500 at increasing doses and concentrations in the treatment of adult women with cellulite.
What is the current status of trial NCT01518907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2012-01. Estimated completion is 2013-02.
What conditions does trial NCT01518907 study?
This clinical trial studies the following conditions: Cellulite, Edematous Fibrosclerotic Panniculopathy.
What interventions are being tested in trial NCT01518907?
The interventions under investigation include: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01518907?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01518907 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulite
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
RECRUITING · NA
-
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
ACTIVE NOT RECRUITING · NA
-
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
COMPLETED · Phase 2
-
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.